The historical rank and industry rank for Ensysce Biosciences's Equity-to-Asset or its related term are showing as below:
ENSC'
s Equity-to-Asset Range Over the Past 10 Years
Min: -18.3 Med: -0.01 Max: 0.74
Current: 0.74
During the past 4 years, the highest Equity to Asset Ratio of Ensysce Biosciences was 0.74. The lowest was -18.30. And the median was -0.01.
ENSC's Equity-to-Asset is ranked better than 57.97% of 1556
companies
in the Biotechnology industry
Industry Median: 0.67
vs ENSC: 0.74
Ensysce Biosciences Equity-to-Asset Historical Data
The historical data trend for Ensysce Biosciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ensysce Biosciences's Equity-to-Asset
For the Biotechnology subindustry, Ensysce Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ensysce Biosciences's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ensysce Biosciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Ensysce Biosciences's Equity-to-Asset falls into.
Ensysce Biosciences Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Ensysce Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Ensysce Biosciences Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Ensysce Biosciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Ensysce Biosciences (Ensysce Biosciences) Business Description
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the?Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENSC has been successfully added to your 